PRLD - Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

• Prelude Therapeutics ( NASDAQ: PRLD ), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent.
• A protein degrader targeted at SMARCA2 ( BRM ) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said.
• “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude ( PRLD ), noted.
• The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023.
• PRLD awaits multiple catalysts in its clinical programs this year.

For further details see: